Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers : A EUROmediCAT Study. / de Jonge, Linda; Garne, Ester; Gini, Rosa; Jordan, Susan E.; Klungsoyr, Kari; Loane, Maria; Neville, Amanda J.; Pierini, Anna; Puccini, Aurora; Thayer, Daniel S.; Tucker, David; Vinkel Hansen, Anne; Bakker, Marian K.

I: Drug Safety, Bind 38, Nr. 11, 11.2015, s. 1083-1093.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

de Jonge, L, Garne, E, Gini, R, Jordan, SE, Klungsoyr, K, Loane, M, Neville, AJ, Pierini, A, Puccini, A, Thayer, DS, Tucker, D, Vinkel Hansen, A & Bakker, MK 2015, 'Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study', Drug Safety, bind 38, nr. 11, s. 1083-1093. https://doi.org/10.1007/s40264-015-0321-9

APA

de Jonge, L., Garne, E., Gini, R., Jordan, S. E., Klungsoyr, K., Loane, M., Neville, A. J., Pierini, A., Puccini, A., Thayer, D. S., Tucker, D., Vinkel Hansen, A., & Bakker, M. K. (2015). Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study. Drug Safety, 38(11), 1083-1093. https://doi.org/10.1007/s40264-015-0321-9

Vancouver

de Jonge L, Garne E, Gini R, Jordan SE, Klungsoyr K, Loane M o.a. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study. Drug Safety. 2015 nov.;38(11):1083-1093. https://doi.org/10.1007/s40264-015-0321-9

Author

de Jonge, Linda ; Garne, Ester ; Gini, Rosa ; Jordan, Susan E. ; Klungsoyr, Kari ; Loane, Maria ; Neville, Amanda J. ; Pierini, Anna ; Puccini, Aurora ; Thayer, Daniel S. ; Tucker, David ; Vinkel Hansen, Anne ; Bakker, Marian K. / Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers : A EUROmediCAT Study. I: Drug Safety. 2015 ; Bind 38, Nr. 11. s. 1083-1093.

Bibtex

@article{56a4de9e649544d39e09e2ce6b9dc99a,
title = "Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study",
abstract = "INTRODUCTION: Research on associations between medication use during pregnancy and congenital anomalies is significative for assessing the safe use of a medicine in pregnancy. Congenital anomaly (CA) registries do not have optimal information on medicine exposure, in contrast to prescription databases. Linkage of prescription databases to the CA registries is a potentially effective method of obtaining accurate information on medicine use in pregnancies and the risk of congenital anomalies.METHODS: We linked data from primary care and prescription databases to five European Surveillance of Congenital Anomalies (EUROCAT) CA registries. The linkage was evaluated by looking at linkage rate, characteristics of linked and non-linked cases, first trimester exposure rates for six groups of medicines according to the prescription data and information on medication use registered in the CA databases, and agreement of exposure.RESULTS: Of the 52,619 cases registered in the CA databases, 26,552 could be linked. The linkage rate varied between registries over time and by type of birth. The first trimester exposure rates and the agreements between the databases varied for the different medicine groups. Information on anti-epileptic drugs and insulins and analogue medicine use recorded by CA registries was of good quality. For selective serotonin reuptake inhibitors, anti-asthmatics, antibacterials for systemic use, and gonadotropins and other ovulation stimulants, the recorded information was less complete.CONCLUSION: Linkage of primary care or prescription databases to CA registries improved the quality of information on maternal use of medicines in pregnancy, especially for medicine groups that are less fully registered in CA registries.",
author = "{de Jonge}, Linda and Ester Garne and Rosa Gini and Jordan, {Susan E.} and Kari Klungsoyr and Maria Loane and Neville, {Amanda J.} and Anna Pierini and Aurora Puccini and Thayer, {Daniel S.} and David Tucker and {Vinkel Hansen}, Anne and Bakker, {Marian K.}",
year = "2015",
month = nov,
doi = "10.1007/s40264-015-0321-9",
language = "English",
volume = "38",
pages = "1083--1093",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "11",

}

RIS

TY - JOUR

T1 - Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers

T2 - A EUROmediCAT Study

AU - de Jonge, Linda

AU - Garne, Ester

AU - Gini, Rosa

AU - Jordan, Susan E.

AU - Klungsoyr, Kari

AU - Loane, Maria

AU - Neville, Amanda J.

AU - Pierini, Anna

AU - Puccini, Aurora

AU - Thayer, Daniel S.

AU - Tucker, David

AU - Vinkel Hansen, Anne

AU - Bakker, Marian K.

PY - 2015/11

Y1 - 2015/11

N2 - INTRODUCTION: Research on associations between medication use during pregnancy and congenital anomalies is significative for assessing the safe use of a medicine in pregnancy. Congenital anomaly (CA) registries do not have optimal information on medicine exposure, in contrast to prescription databases. Linkage of prescription databases to the CA registries is a potentially effective method of obtaining accurate information on medicine use in pregnancies and the risk of congenital anomalies.METHODS: We linked data from primary care and prescription databases to five European Surveillance of Congenital Anomalies (EUROCAT) CA registries. The linkage was evaluated by looking at linkage rate, characteristics of linked and non-linked cases, first trimester exposure rates for six groups of medicines according to the prescription data and information on medication use registered in the CA databases, and agreement of exposure.RESULTS: Of the 52,619 cases registered in the CA databases, 26,552 could be linked. The linkage rate varied between registries over time and by type of birth. The first trimester exposure rates and the agreements between the databases varied for the different medicine groups. Information on anti-epileptic drugs and insulins and analogue medicine use recorded by CA registries was of good quality. For selective serotonin reuptake inhibitors, anti-asthmatics, antibacterials for systemic use, and gonadotropins and other ovulation stimulants, the recorded information was less complete.CONCLUSION: Linkage of primary care or prescription databases to CA registries improved the quality of information on maternal use of medicines in pregnancy, especially for medicine groups that are less fully registered in CA registries.

AB - INTRODUCTION: Research on associations between medication use during pregnancy and congenital anomalies is significative for assessing the safe use of a medicine in pregnancy. Congenital anomaly (CA) registries do not have optimal information on medicine exposure, in contrast to prescription databases. Linkage of prescription databases to the CA registries is a potentially effective method of obtaining accurate information on medicine use in pregnancies and the risk of congenital anomalies.METHODS: We linked data from primary care and prescription databases to five European Surveillance of Congenital Anomalies (EUROCAT) CA registries. The linkage was evaluated by looking at linkage rate, characteristics of linked and non-linked cases, first trimester exposure rates for six groups of medicines according to the prescription data and information on medication use registered in the CA databases, and agreement of exposure.RESULTS: Of the 52,619 cases registered in the CA databases, 26,552 could be linked. The linkage rate varied between registries over time and by type of birth. The first trimester exposure rates and the agreements between the databases varied for the different medicine groups. Information on anti-epileptic drugs and insulins and analogue medicine use recorded by CA registries was of good quality. For selective serotonin reuptake inhibitors, anti-asthmatics, antibacterials for systemic use, and gonadotropins and other ovulation stimulants, the recorded information was less complete.CONCLUSION: Linkage of primary care or prescription databases to CA registries improved the quality of information on maternal use of medicines in pregnancy, especially for medicine groups that are less fully registered in CA registries.

U2 - 10.1007/s40264-015-0321-9

DO - 10.1007/s40264-015-0321-9

M3 - Journal article

C2 - 26153398

VL - 38

SP - 1083

EP - 1093

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 11

ER -

ID: 162714270